Senaste nyheterna

26 Juli 2021 08:02

Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria

Alexion’s Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH).

23 Juli 2021 10:04

Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern

Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively

21 Juli 2021 14:47

Acquisition of Alexion completed

AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.

19 Juli 2021 08:03

Imfinzi approved in China for the treatment of extensive-stage small cell lung cancer

AstraZeneca’s Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with standard of care platinum chemotherapy (etoposide plus a choice of either carboplatin or cisplatin).

16 Juli 2021 08:05

Status on FDA Advisory Committee vote on roxadustat in anaemia of chronic kidney disease

The Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent (NDD) adult patients, and 12 to 2 that the benefit-risk profile of roxadustat does not support approval for the treatment of a

14 Juli 2021 08:14

AstraZeneca receives final regulatory clearance for the proposed acquisition of Alexion from the UK’s Competition and Markets Authority

The UK Competition and Markets Authority has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion). As a result, the acquisition is expected to close on 21 July 2021.

8 Juli 2021 08:03

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma

AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.

Kommande event

Inbjudan till webcast för media torsdagen den 29 juli 2021 kl 10.00 med anledning av AstraZenecas resultatrapport för första halvåret 2021

Tid 29 Juli 2021 10:00 – 10:00

Sociala medier

Presskontakt

Christina Malmberg Hägerstrand

Presskontakt Presschef, AstraZeneca AB christina.malmberghagerstrand@astrazeneca.com +46 8 552 531 06

Jacob Lund

Presskontakt Kommunikationsdirektör AstraZeneca AB, AstraZeneca Nordic, Global hållbarhet och Styrelseordförande Leif Johanssons kontor jacob.lund@astrazeneca.com 08 553 260 20 Mobil: 072 560 21 57